L3VLUP
ProSign in

INMD · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INMDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INMD
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterINMDVRTX
Q3 20201 holders, $876k31 holders, $21.9bn
Q4 20205 holders, $37m30 holders, $18.4bn
Q1 202112 holders, $245m31 holders, $15.4bn
Q2 202111 holders, $360m30 holders, $12.7bn
Q3 202114 holders, $734m35 holders, $10.1bn
Q4 202112 holders, $695m28 holders, $12.4bn
Q1 202213 holders, $471m23 holders, $16.1bn
Q2 202210 holders, $287m25 holders, $18.1bn
Q3 202210 holders, $271m22 holders, $18.4bn
Q4 20227 holders, $263m28 holders, $18.4bn
Q1 20239 holders, $248m26 holders, $21.4bn
Q2 20237 holders, $247m27 holders, $24.7bn
Q3 20236 holders, $159m33 holders, $24.3bn
Q4 20234 holders, $81m32 holders, $28.6bn
Q1 20244 holders, $77m31 holders, $29.8bn
Q2 20245 holders, $81m29 holders, $33.4bn
Q3 20245 holders, $66m27 holders, $33.5bn
Q4 20244 holders, $63m26 holders, $28.5bn
Q1 20253 holders, $53m21 holders, $35.4bn
Q2 20254 holders, $39m21 holders, $32.3bn
Q3 20253 holders, $68m22 holders, $25.9bn
Q4 20253 holders, $76m26 holders, $31.8bn
Q1 20263 holders, $73m25 holders, $31.8bn
Q2 20263 holders, $75m26 holders, $34.6bn
INMD

Inmode LTD

Holders
4
Reported value
$77m
Buyers
1
Sellers
3

Breadth -2 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INMD (0)

None.

Only VRTX (27)

AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →